These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 33623860)

  • 1. Strategies for active and passive pediatric RSV immunization.
    Eichinger KM; Kosanovich JL; Lipp M; Empey KM; Petrovsky N
    Ther Adv Vaccines Immunother; 2021; 9():2515135520981516. PubMed ID: 33623860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prefusion RSV F Immunization Elicits Th2-Mediated Lung Pathology in Mice When Formulated With a Th2 (but Not a Th1/Th2-Balanced) Adjuvant Despite Complete Viral Protection.
    Eichinger KM; Kosanovich JL; Gidwani SV; Zomback A; Lipp MA; Perkins TN; Oury TD; Petrovsky N; Marshall CP; Yondola MA; Empey KM
    Front Immunol; 2020; 11():1673. PubMed ID: 32849580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prior respiratory syncytial virus infection reduces vaccine-mediated Th2-skewed immunity, but retains enhanced RSV F-specific CD8 T cell responses elicited by a Th1-skewing vaccine formulation.
    Eichinger KM; Kosanovich JL; Perkins TN; Oury TD; Petrovsky N; Marshall CP; Yondola MA; Empey KM
    Front Immunol; 2022; 13():1025341. PubMed ID: 36268035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
    Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
    Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Passive and active immunization against respiratory syncytial virus for the young and old.
    Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
    Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
    J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation of the prefusion RSV F protein with a Th1/Th2-balanced adjuvant provides complete protection without Th2-skewed immunity in RSV-experienced young mice.
    Kosanovich JL; Eichinger KM; Lipp MA; Yondola MA; Perkins TN; Empey KM
    Vaccine; 2020 Sep; 38(41):6357-6362. PubMed ID: 32829976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization.
    Raghunandan R; Lu H; Zhou B; Xabier MG; Massare MJ; Flyer DC; Fries LF; Smith GE; Glenn GM
    Vaccine; 2014 Nov; 32(48):6485-92. PubMed ID: 25269094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delta inulin-derived adjuvants that elicit Th1 phenotype following vaccination reduces respiratory syncytial virus lung titers without a reduction in lung immunopathology.
    Wong TM; Petrovsky N; Bissel SJ; Wiley CA; Ross TM
    Hum Vaccin Immunother; 2016 Aug; 12(8):2096-2105. PubMed ID: 27215855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New and Emerging Passive Immunization Strategies for the Prevention of RSV Infection During Infancy.
    Domachowske JB
    J Pediatric Infect Dis Soc; 2024 Jul; 13(Supplement_2):S115-S124. PubMed ID: 38554101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RSV Prevention in All Infants: Which Is the Most Preferable Strategy?
    Esposito S; Abu Raya B; Baraldi E; Flanagan K; Martinon Torres F; Tsolia M; Zielen S
    Front Immunol; 2022; 13():880368. PubMed ID: 35572550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
    Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maternal immunization with RSV fusion glycoprotein vaccine and substantial protection of neonatal baboons against respiratory syncytial virus pulmonary challenge.
    Welliver RC; Papin JF; Preno A; Ivanov V; Tian JH; Lu H; Guebre-Xabier M; Flyer D; Massare MJ; Glenn G; Ellingsworth L; Smith G
    Vaccine; 2020 Jan; 38(5):1258-1270. PubMed ID: 31761502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.
    Wiegand MA; Gori-Savellini G; Gandolfo C; Papa G; Kaufmann C; Felder E; Ginori A; Disanto MG; Spina D; Cusi MG
    J Virol; 2017 May; 91(10):. PubMed ID: 28250126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Historical Perspective on Respiratory Syncytial Virus Prevention: A Journey Spanning Over Half a Century From the Setback of an Inactive Vaccine Candidate to the Success of Passive Immunization Strategy.
    Noor A; Krilov LR
    J Pediatric Infect Dis Soc; 2024 Jul; 13(Supplement_2):S103-S109. PubMed ID: 38577737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profile of respiratory syncytial virus prefusogenic fusion protein nanoparticle vaccine.
    Blunck BN; Rezende W; Piedra PA
    Expert Rev Vaccines; 2021 Apr; 20(4):351-364. PubMed ID: 33733995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention strategies for respiratory syncytial virus: passive and active immunization.
    Englund JA
    J Pediatr; 1999 Aug; 135(2 Pt 2):38-44. PubMed ID: 10431138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maternal immunization with respiratory syncytial virus fusion protein formulated with a novel combination adjuvant provides protection from RSV in newborn lambs.
    Garg R; Latimer L; Wang Y; Simko E; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Vaccine; 2016 Jan; 34(2):261-269. PubMed ID: 26616551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.